I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has […]
Shinya Yamanaka Interview on Clinical Use of IPSC Read More »
I had the idea of something called Prostate cancer postcards. In a few days it will be the 5-year anniversary of my diagnosis with a very serious form of prostate cancer. So far since then I’ve been doing pretty well (knock on wood). I am still getting PSA tested and life still has a cancer thread
Prostate cancer postcards Read More »
The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related
Advanced Cell Technology pub: Trial for Macular Degeneration Read More »
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based
BioTime Cell Cure Files IND with FDA for ES cell AMD therapy Read More »
The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many
CIRM 2.0 Should Include Bridges Training Program Read More »
Sperm and brain tumors? Sometimes in science there are unexpected threads tying seemingly very different things together. Unraveling the knots in these threads can lead to new insights into important developmental processes and mechanisms of disease. My lab studies epigenomic and transcription factors including a molecule called histone variant H3.3 (more here on H3.3). H3.3
What is the connection between sperm and brain tumors? Read More »
In a major first for the stem cell and regenerative medicine fields, a patient in Japan today received a pioneering transplant of a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells, also known by the acronym IPSC. This is the first ever iPS cell-based transplant into a human. The patient is
Landmark: patient receives first ever iPS cell based transplant Read More »
The reviews of a STAP paper submitted to and rejected by the journal Science in 2012 were posted at Retraction Watch yesterday. They filled in some gaps in the puzzle of the series of events that led to such flawed science being published in Nature in January 2014, but the reviews also raised more questions. Today, more STAP paper
STAP papers blistered by Nature’s own reviewers were then accepted Read More »
Before the two STAP cell papers were published in Nature in January of 2014, much of the same data was reportedly submitted as single papers to other high-profile journals including Science. In these cases, the proto-STAP papers as we might call them were rejected. But why? Until now we largely could only speculate. However, the reviews
Full Reviews of Rejected STAP Paper Point to Early Signs of Big Trouble Read More »
The last two years at Nature Magazine have seen a surprising wave of paper retractions. In 2013 and now just so far in 2014, Nature has retracted a total of 14 papers. How unusual is that? Historically, Nature retracts relatively few papers, perhaps just under two per year on average. What the heck has been going on in 2013-2014? Let’s break it
Could Nature’s 2-year torrent of paper retractions be a good thing? Read More »